True. But, I could be wrong (and I will do backflips if I am!), a plant dedicated to producing this product would decrease the hassle of them producing it themselves and wading through more FDA red tape. In the CC, Mr. Phykitt explained that there are numerous "hoops" to run through (from FDA) to produce this product, and Big Pharma would have to jump those same hoops when they prepare to produce it, so why not let someone else do it instead of them?
Big Pharma DOES know these patents exist and they ARE aware of Mr. Phykitt. If you listened to the CC, there were some BIG things that they weren't saying, insinuating that they already have good connections and (to me, anyway) that some big $$$ were already sitting on the sidelines ready to jump in. That really made my ears perk up a little!
Now, I could be all wet, but I actually get the impression that Mr. Phykitt only went public so he could have restricted shares to use (valued by the single patent appraisal) to fund his venture. It almost seemed like the 92m float is inconsequential to him.
This is the most intriguing thing, to me, about this company - it's like we are insignificant (the float people) but the pps IS NOT! The higher pps he can get, the more valuable the restricted shares will be to fund this project.
I just can't see them jumping in 3-5 months after they begin when 14 months is the targeted date to supply shelves. Believe me, I would LOVE to be wrong.
We may be discussing apples and oranges, but both want the same thing.
Go PHAR
News 
Market Data 
Discover 
AI
